Emilie Høegholm Ernst Lauridsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Emilie Høegholm Ernst Lauridsen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Allan Rasmussen
Department of Clinical Medicine University of Copenhagen København K Denmark
1 shared publicationGerda Elisabeth Villadsen
Department of Hepatology and Gastroenterology Aarhus University Hospital Aarhus Denmark
1 shared publicationHenning Grønbæk
Department of Hepatology and Gastroenterology Aarhus University Hospital Aarhus Denmark
1 shared publicationMette Bak Nielsen
Department of Clinical Medicine Aarhus University Aarhus Denmark
1 shared publication- Moises Alberto Suarez-Zdunek
Viroimmunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital—Rigshospitalet, 2100 Copenhagen, Denmark
1 shared publication Rasmus Hvidbjerg Gantzel
Department of Hepatology and Gastroenterology Aarhus University Hospital Aarhus Denmark
1 shared publication
Latest Publications
- Open Access
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70468
Soluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients
Background and Aims: Post liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long‐term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB‐4) score and FibroScan. Methods: In the Danish Comorbidity in Liver Transplant Recipients study (DACOLT) we included 105 LT recipients at Aarhus University Hospital. We reviewed patient records and collected plasma for measurements of sCD163 and FIB‐4. Liver stiffness was assessed using FibroScan. Liver biopsies performed n = 33) were investigated by the Banff score and the METAVIR fibrosis score. Results: The majority (86%) had FibroScan with transient elastography ρ = 0.38, p < 0.001) and remained independently associated after multivariable adjustment (β = 0.14, p < 0.0002), corresponding to a 15.2% increase in liver stiffness per 1 mg/L increase in sCD163. In patients with liver biopsies, sCD163 levels were significantly higher in those with METAVIR stage F2–F4 compared to F0–F1 (5.04 vs. 2.35 mg/L, p = 0.018), and sCD163 correlated with histological fibrosis stage ( ρ = 0.40, p = 0.029). At a cutoff of 3.86 mg/L, sCD163 identified METAVIR F2–4 fibrosis with 80% sensitivity and 85% specificity (AUC = 0.94). Conclusions: In this cohort of LT recipients, sCD163 was associated with both liver stiffness and histological fibrosis. These findings support sCD163 as a promising noninvasive biomarker for detection and monitoring of liver fibrosis post‐LT, warranting evaluation in larger, prospective studies.
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70468
Open AccessSoluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients
Background and Aims: Post liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long‐term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB‐4) score and FibroScan. Methods: In the Danish Comorbidity in Liver Transplant Recipients study (DACOLT) we included 105 LT recipients at Aarhus University Hospital. We reviewed patient records and collected plasma for measurements of sCD163 and FIB‐4. Liver stiffness was assessed using FibroScan. Liver biopsies performed n = 33) were investigated by the Banff score and the METAVIR fibrosis score. Results: The majority (86%) had FibroScan with transient elastography ρ = 0.38, p < 0.001) and remained independently associated after multivariable adjustment (β = 0.14, p < 0.0002), corresponding to a 15.2% increase in liver stiffness per 1 mg/L increase in sCD163. In patients with liver biopsies, sCD163 levels were significantly higher in those with METAVIR stage F2–F4 compared to F0–F1 (5.04 vs. 2.35 mg/L, p = 0.018), and sCD163 correlated with histological fibrosis stage ( ρ = 0.40, p = 0.029). At a cutoff of 3.86 mg/L, sCD163 identified METAVIR F2–4 fibrosis with 80% sensitivity and 85% specificity (AUC = 0.94). Conclusions: In this cohort of LT recipients, sCD163 was associated with both liver stiffness and histological fibrosis. These findings support sCD163 as a promising noninvasive biomarker for detection and monitoring of liver fibrosis post‐LT, warranting evaluation in larger, prospective studies.